ahlam1399
09-01-2015, 12:19 PM
UPDATE 1-Valeant picks up AstraZeneca psoriasis drug after Amgen exit
Sept 1 (Reuters) - Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4976a27c/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1LMvi2-ixCg:_7**FJplxe0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1LMvi2-ixCg:_7**FJplxe0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/1LMvi2-ixCg
Sept 1 (Reuters) - Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4976a27c/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1LMvi2-ixCg:_7**FJplxe0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1LMvi2-ixCg:_7**FJplxe0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=1LMvi2-ixCg:_7**FJplxe0:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/1LMvi2-ixCg